$IMVT

Immunovant, Inc. (IMVT): Submission of Matters to a Vote of Security Holders

Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 2, 2026, Immunovant, Inc. ( “ Immunovant ” ) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ” ). There were 198,373,370 shares of common stock and Series A preferred stock represented

Original reporting
Published Sep 3, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$IMVT
Neutral
high confidence
Mentioned
$IMVT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IMVTNeutralLow
01

Why it matters

The disclosure confirms the outcome of three proxy proposals: election of three directors, ratification of Ernst & Young LLP as independent auditor for FY ending March 31, 2027, and a non-binding advisory approval of named executive officer compensation.

02

Market read

Routine proxy vote results, with no new guidance, trial updates, or transactions disclosed.

03

What to watch

Non-binding say-on-pay and auditor ratification are typically not market-moving; any impact would require additional context not present here.

Relevance 6/10Novelty 2/10Timing: Filed with SEC on 2026-09-03 after the 2026 annual meeting held 2026-09-02.

Background

The company filed an 8-K under Item 5.07 summarizing matters voted on at its 2026 annual meeting of stockholders.

Company-level read

Ticker impact

$IMVTNeutralHigh confidence
Context

Immunovant disclosed 2026 annual meeting voting results, including director elections and ratification of Ernst & Young LLP for FY ending March 31, 2027.

Expected impact

Low likelihood of a sustained move; any reaction should be muted unless paired with other catalysts.

Evidence & confidence

The filing reports proxy vote outcomes (board election, auditor ratification, non-binding say-on-pay) without new business, clinical, or financial datapoints.

Market effects

Minimal. Governance vote outcomes do not change biotech sector fundamentals.

Minimal, US-listed issuer filing.

Minimal.

Counterpoint

Traders could briefly reprice if the vote results imply unusual dissent, but the article provides no dissent narrative or threshold triggers.

Key entities

  • Immunovant, Inc.

    US-listed biotech company filing the 8-K with annual meeting voting results.

  • Ernst & Young LLP

    Ratified by stockholders as independent registered public accounting firm for FY ending March 31, 2027.

  • Jacob Bauer

    Elected to the board at the annual meeting.

  • Douglas Hughes

    Elected to the board at the annual meeting.

  • Robert Susman

    Elected to the board at the annual meeting.

Related articles

$IMVTMedAI 8/10

Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case

Immunovant (IMVT) reported a Phase 2b trial failure for IMVT-1402 in CLE, discontinuing development. Despite missing the primary endpoint, the drug showed positive trends and a favorable safety profile. IMVT-1402 is still being tested in five other autoimmune diseases, with data expected from 2027. The company has $797.8M in cash, and hedge fund interest has increased.

$IMVTHighAI 8/10

Why is Immunovant stock sliding today?

Immunovant stock fell 6.1% to $35.00 after its IMVT-1402 drug failed to meet the primary endpoint in a cutaneous lupus erythematosus trial. The company discontinued the program, though other indications remain unaffected. Parent company Roivant Sciences also saw shares decline. The broader market was slightly lower.

$IMVTHighAI 8/10

Immunovant stock falls after lupus drug trial misses goal

Immunovant (IMVT) shares dropped 6% after its lupus drug trial failed to meet the primary endpoint. The study did not show statistical significance in improving CLE symptoms. The company plans to halt development of IMVT-1402 for this indication but will continue trials for other autoimmune diseases. According to Immunovant, the drug showed a favorable safety profile.